Sert, Berranur
Gulden, Gamze
Teymur, Tarik
Ay, Yasin
Turan, Raife Dilek
Unaldi, Onur Mert
Guzenge, Elanur
Erdil, Hamza Emir
Isik, Sevim
Oz, Pinar
Bozkurt, Ilknur
Ozer, Samed
Yurdakul, Tahire
Kamali, Osman http://orcid.org/0009-0003-2055-8247
Ovali, Ercument
Tarhan, Nevzat
Tastan, Cihan http://orcid.org/0000-0002-4173-6634
Funding for this research was provided by:
All funding in the project was supported by the Presidency of Turkish Health Institutes (TUSEB) with grant number 4293.
Article History
Received: 22 August 2023
Revised: 20 November 2023
Accepted: 27 November 2023
First Online: 14 December 2023
Competing interests
: CT, BS, GG, TT, and YA are inventors of patent applications (pending) including “Allogeneic CAR-T cells expressing bispecific chimeric antigen receptors (CARs) targeting CD19 along with CD20 or CD22” (PCT/TR2023/050541 and 2022/009703) at Turkish Patent and Trademark Office. No other author has a competing interest except for these authors.
: In vitro and in vivo studies were approved by the Acibadem University and Acibadem Healthcare Institutions Medical Research Ethics Committee (ATADEK-2019-17/31). All animal studies have been approved by Acıbadem University Animal Experiments Local Ethics Committee (ACU-HADYEK; 11.13.2019).